AROCELL AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.372 SEK | +0.54% |
|
-3.88% | -14.87% |
| Apr. 18 | Swedish Diagnostics Company AroCell Secures US Patent | MT |
| Feb. 22 | AroCell AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
AroCell publ AB is a Sweden-based diagnostic Company engaged in the development of markers for determination of cell growth (TK 210) and apoptosis. The Company's principal product candidate, TK-immuno/hem, is a test for monitoring and follow up of blood cancer. The test is based on a patented technology, which have already been evaluated in an early product prototype ELISA method. Apart from that, the Company develops a marker for solid tumor cancer disease. The AroCell cooperates with partners within development, production and sales.
Calendar
2024-05-02
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -14.87% | 7.82M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- AROC Stock
- News AroCell AB
- AroCell Wins Regulatory Nod for Typhoid Fever Rapid Test in Ethiopia
